The program is designed to support the collection and analysis of "informative molecular activity and cellular feature signatures" in response to siRNAs, small molecules, and other perturbing agents in a variety of cell types.
Although Quark initially expects to market the drug as a treatment for a rare condition known as non-arteritic anterior ischemic optic neuropathy, it hopes it can eventually develop it as a glaucoma treatment.
Alnylam previously released data from a phase IIa study of the drug in RSV-infected adult lung transplant patients showing that it was safe and well tolerated. While the data indicated a certain level of efficacy, this demonstration was less robust than many industry watchers had expected.
The company's core technology is dubbed PRINT, or Pattern Replication In Non-wetting Templates. It involves making templates of specific patterns, on which a proprietary non-stick polymer is applied to create a mold.
The collaboration will focus on Bioo's Targeted Transport Technology, which involves joining a carrier agent to a monoclonal antibody to produce a conjugate that is then loaded with an RNAi molecule such as an siRNA or miRNA mimic, to deliver anti-HIV siRNAs into T cells.